The use of EGFR TKIs as adjuvant therapy in early‐stage NSCLC patients with EGFR mutations is not recommended by the NCCN guideline,13 but several studies recently reported that EGFR TKIs could prolong RFS in stage II and stage IIIA patients compared to those receiving conventional intravenous chemotherapy39, 40, 41 However, the benefit of OS for patients with EGFR mutant NSCLC who receive TKI as adjuvant therapy after complete surgical resection is still being studied. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.